Sub menu

 
 

Appendix 2 to the Guideline on the evaluation of anticancer medicinal products in man (CPMP/EWP/205/95 Rev. 3) on confirmatory studies in haematological malignancies

We have adopted this International Scientific Guideline - EMA/CHMP/EWP/520088/2008.

Last updated

About this guideline

Overseas effective date: 1 September 2010

Note: Although this guideline has been superseded, it remains our formally adopted version. We will look to adopt the most current version of this guideline in due course.

Categories: Clinical efficacy and safety | Antineoplastic and immunomodulating agents

TGA annotations: Nil

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

For more information see International scientific guidelines adopted in Australia.

Help us improve the Therapeutic Goods Administration site